{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:02:21Z","timestamp":1784372541404,"version":"3.55.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Rare diseases affect a small percentage of an individual country\u2019s population; however, with over 7,000 in total, rare diseases represent a significant disease burden impacting up to 10% of the world\u2019s population. Despite this, there are no approved treatments for almost 95% of rare diseases, and the existing treatments are cost-intensive for the patients. More than 70% of rare diseases are genetic in nature, with patient-specific mutations. This calls for the need to have personalised and patient-specific preclinical models that can lead to effective, speedy, and affordable therapeutic options. Complex <jats:italic>in vitro<\/jats:italic> models (CIVMs), including those using induced pluripotent stem cells (iPSCs), organoids, and organs-on-chips are emerging as powerful human-based pre-clinical systems with the capacity to provide efficacy data enabling drugs to move into clinical trials. In this narrative review, we discuss how CIVMs are providing insights into biomedical research on rare diseases. We also discuss how these systems are being used in clinical trials to develop efficacy models for rare diseases. Finally, we propose recommendations on how human relevant CIVMs could be leveraged to increase translatability of basic, applied and nonclinical research outcomes in the field of rare disease therapeutics in developed as well as middle-and low-income countries.<\/jats:p>","DOI":"10.3389\/fcell.2025.1526306","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T06:43:37Z","timestamp":1737960217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Human-based complex in vitro models: their promise and potential for rare disease therapeutics"],"prefix":"10.3389","volume":"13","author":[{"given":"Surat","family":"Parvatam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pistollato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay J.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabia","family":"Furtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devashree","family":"Jahagirdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohua","family":"Chakraborty Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshita","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saveetha","family":"Meganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12038-023-00412-9","article-title":"Spinal muscular atrophy: molecular mechanism of pathogenesis, diagnosis, therapeutics, and clinical trials in the Indian context","volume":"49","author":"Aasdev","year":"2024","journal-title":"J. Biosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1194\/jlr.M081323","article-title":"Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation","volume":"59","author":"Allende","year":"2018","journal-title":"J. Lipid Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2022960118","DOI":"10.1073\/pnas.2022960118","article-title":"Prednisolone rescues Duchenne muscular dystrophy phenotypes in human pluripotent stem cell-derived skeletal muscle in vitro","volume":"118","author":"Al Tanoury","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1038\/s41467-024-48864-3","article-title":"Roadblocks confronting widespread dissemination and deployment of Organs on Chips","volume":"15","author":"Alver","year":"2024","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fgene.2020.00415","article-title":"Review: understanding rare genetic diseases in low resource regions like Jammu and Kashmir - India","volume":"11","author":"Angural","year":"2020","journal-title":"Front. Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1093\/hmg\/ddv297","article-title":"Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells","volume":"24","author":"Awad","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"B7","volume-title":"Despite availability of funds, patients with rare Fabry Disease yet to be given treatment, says support society","author":"Bureau","year":"2023"},{"key":"B8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1119606","DOI":"10.3389\/fbioe.2023.1119606","article-title":"Induced pluripotent stem cell-based therapies for organ fibrosis","volume":"11","author":"Cheng","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"059845","DOI":"10.1242\/bio.059845","article-title":"Cerebral organoids in primary progressive multiple sclerosis reveal stem cell and oligodendrocyte differentiation defect","volume":"12","author":"Daviaud","year":"2023","journal-title":"Biol. Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jcf.2023.03.004","article-title":"FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes","volume":"22","author":"de Poel","year":"2023","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"103660","DOI":"10.1016\/j.ebiom.2021.103660","article-title":"Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis","volume":"73","author":"Dumas","year":"2021","journal-title":"EBioMedicine"},{"key":"B15","doi-asserted-by":"publisher","article-title":"Raising the voice for rare diseases: under the spotlight for equity. eClinicalMedicine 57","year":"2023","DOI":"10.1016\/j.eclinm.2023.101941"},{"key":"B16","doi-asserted-by":"publisher","first-page":"CD006663","DOI":"10.1002\/14651858.CD006663.pub4","article-title":"Enzyme replacement therapy for Anderson\u2010Fabry disease","volume":"2016","author":"El Dib","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S2213-8587(19)30006-3","article-title":"Spotlight on rare diseases","volume":"7","author":"Endocrinology","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun. Med."},{"key":"B19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/B978-0-323-85765-9.00005-9","article-title":"Chapter 7 - modeling inherited retinal dystrophies using induced pluripotent stem cells","volume-title":"Current progress in iPSC disease modeling","author":"Faynus","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","article-title":"A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act","volume":"18","author":"Fermaglich","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/TRD-160005","article-title":"Lysosomal storage diseases","volume":"2","author":"Ferreira","year":"2024","journal-title":"Transl. Sci. Rare Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1089\/scd.2024.0105","article-title":"Modeling choroideremia disease with isogenic induced pluripotent stem cells","volume":"33","author":"Fonseca","year":"2024","journal-title":"Stem Cells Dev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/JLB.5HI1117-454RR","article-title":"Frontline Science: pathological conditioning of human neutrophils recruited to the airway milieu in cystic fibrosis","volume":"104","author":"Forrest","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"103839","DOI":"10.1016\/j.msard.2022.103839","article-title":"Using MS induced pluripotent stem cells to investigate MS aetiology","volume":"63","author":"Fortune","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The Dystrophin Complex: structure, function and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ana.26336","article-title":"MS\u2010Driven metabolic alterations are recapitulated in iPSC\u2010derived astrocytes","volume":"91","author":"Ghirotto","year":"2022","journal-title":"Ann. Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101659","DOI":"10.1016\/j.xcrm.2024.101659","article-title":"Isogenic patient-derived organoids reveal early neurodevelopmental defects in spinal muscular atrophy initiation","volume":"5","author":"Grass","year":"2024","journal-title":"Cell. Rep. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1530\/EJE-20-1453","article-title":"The phenotypic spectrum associated with OTX2 mutations in humans","volume":"185","author":"Gregory","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3310\/nihropenres.1115214.1","article-title":"Rare diseases research landscape project report","volume":"3","author":"Group","year":"2023","journal-title":"NIHR Open Res."},{"key":"B30","article-title":"Hypermobile ehlers-danlos syndrome","volume-title":"GeneReviews\u00ae","author":"Hakim","year":"1993"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103321","DOI":"10.1016\/j.scr.2024.103321","article-title":"Generation of the human induced pluripotent stem cell line (IBKMOLi003-A) from PBMCs of a vascular Ehlers-Danlos syndrome (vEDS) patient carrying the heterozygous nonsense mutation c.430C > T (p.Q105*) in the COL3A1 gene","volume":"75","author":"H\u00f6pperger","year":"2024","journal-title":"Stem Cell. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/s41419-018-1081-0","article-title":"Cell cycle inhibitors protect motor neurons in an organoid model of Spinal Muscular Atrophy","volume":"9","author":"Hor","year":"2018","journal-title":"Cell. Death Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"RP90575","DOI":"10.7554\/eLife.90575","article-title":"Disease modeling and pharmacological rescue of autosomal dominant retinitis pigmentosa associated with RHO copy number variation","volume":"12","author":"Kandoi","year":"2024","journal-title":"eLife"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1059021","DOI":"10.3389\/fphys.2022.1059021","article-title":"The importance of dystrophin and the dystrophin associated proteins in vascular smooth muscle","volume":"13","author":"Kaplan","year":"2022","journal-title":"Front. Physiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"102683","DOI":"10.1016\/j.scr.2022.102683","article-title":"Generation of human induced pluripotent stem cells from cystic fibrosis patient carrying nonsense mutation (p.S308X) in CFTR gene","volume":"60","author":"Khor","year":"2022","journal-title":"Stem Cell. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","article-title":"Human kidney organoids reveal the role of glutathione in Fabry disease","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrd.2017.140","article-title":"FDA OKs first in vitro route to expanded approval","volume":"16","author":"Kingwell","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion","volume":"45","author":"Koenig","year":"1989","journal-title":"Am. J. Hum. Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell."},{"key":"B40","doi-asserted-by":"publisher","first-page":"102232","DOI":"10.1016\/j.scr.2021.102232","article-title":"Generation of two induced pluripotent stem cell lines (RCMGi004-A and -B) from human skin fibroblasts of a cystic fibrosis patient with compound heterozygous F508del\/W1282X mutations in CFTR gene","volume":"52","author":"Kondrateva","year":"2021","journal-title":"Stem Cell. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell."},{"key":"B42","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/978-3-031-27681-1_81","article-title":"Modeling retinitis pigmentosa with patient-derived iPSCs","volume":"1415","author":"Leong","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13287-023-03564-5","article-title":"Application of patient-derived induced pluripotent stem cells and organoids in inherited retinal diseases","volume":"14","author":"Liang","year":"2023","journal-title":"Stem Cell. Res. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"109856","DOI":"10.1016\/j.exer.2024.109856","article-title":"Modeling autosomal dominant retinitis pigmentosa by using patient-specific retinal organoids with a class-3 RHO mutation","volume":"241","author":"Lin","year":"2024","journal-title":"Exp. Eye Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fmolb.2020.00224","article-title":"Human iPSC-based models for the development of therapeutics targeting neurodegenerative lysosomal storage diseases","volume":"7","author":"Luciani","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.celrep.2018.03.091","article-title":"Three-dimensional human iPSC-derived artificial skeletal muscles model muscular dystrophies and enable multilineage tissue engineering","volume":"23","author":"Maffioletti","year":"2018","journal-title":"Cell. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"103485","DOI":"10.1016\/j.scr.2024.103485","article-title":"Generation of two iPSC lines from vascular Ehlers-Danlos Syndrome (vEDS) patients carrying a missense mutation in COL3A1 gene","volume":"79","author":"Manhas","year":"2024","journal-title":"Stem Cell. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"878311","DOI":"10.3389\/fcell.2022.878311","article-title":"Long-term culture of patient-derived cardiac organoids recapitulated Duchenne muscular dystrophy cardiomyopathy and disease progression","volume":"10","author":"Marini","year":"2022","journal-title":"Front. Cell. Dev. Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"jcs221739","DOI":"10.1242\/jcs.221739","article-title":"Lysosomal storage disorders - challenges, concepts and avenues for therapy: beyond rare diseases","volume":"132","author":"Marques","year":"2019","journal-title":"J. Cell. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"S22-S27","DOI":"10.1016\/j.jcf.2017.10.006","article-title":"Ion channels as targets to treat cystic fibrosis lung disease","volume":"17","author":"Martin","year":"2018","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1038\/s41591-023-02333-4","article-title":"Rare-disease researchers pioneer a unique approach to clinical trials","volume":"29","author":"May","year":"2023","journal-title":"Nat. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.21686","article-title":"The challenges of clinical trials in rare diseases","volume":"187","author":"Mellerio","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/mus.23810","article-title":"Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy","volume":"48","author":"Mendell","year":"2013","journal-title":"Muscle Nerve"},{"key":"B54","doi-asserted-by":"publisher","first-page":"101744","DOI":"10.1016\/j.scr.2020.101744","article-title":"Generation of an induced pluripotent stem cell line (MHHi018-A) from a patient with Cystic Fibrosis carrying p.Asn1303Lys (N1303K) mutation","volume":"44","author":"Merkert","year":"2020","journal-title":"Stem Cell. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13023-021-01901-6","article-title":"Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases","volume":"16","author":"Miller","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12916-023-03113-0","article-title":"A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies","volume":"21","author":"Modi","year":"2023","journal-title":"BMC Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"102319","DOI":"10.1016\/j.scr.2021.102319","article-title":"Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis","volume":"53","author":"Mutukula","year":"2021","journal-title":"Stem Cell. Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","article-title":"Occurrence of Parkinson\u2019s syndrome in type I Gaucher disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM Mon. J. Assoc. Physicians"},{"key":"B59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.stem.2021.04.015","article-title":"Overcoming translational barriers in modeling macular degenerations","volume":"28","author":"Nolan","year":"2021","journal-title":"Cell. Stem Cell."},{"key":"B61","doi-asserted-by":"publisher","first-page":"7570","DOI":"10.3390\/ijms23147570","article-title":"Genetic background matters: population-based studies in model organisms for translational research","volume":"23","author":"Olgu\u00edn","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e174179","DOI":"10.1172\/jci.insight.174179","article-title":"Phototoxicity avoidance is a potential therapeutic approach for retinal dystrophy caused by EYS dysfunction","volume":"9","author":"Otsuka","year":"2024","journal-title":"JCI Insight"},{"key":"B63","doi-asserted-by":"publisher","first-page":"18054","DOI":"10.1073\/pnas.1207889109","article-title":"Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease","volume":"109","author":"Panicker","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jcf.2021.10.004","article-title":"Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip","volume":"21","author":"Plebani","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B66","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"B67","article-title":"Spinal muscular atrophy","volume-title":"GeneReviews\u00ae","author":"Prior","year":"1993"},{"key":"B68","doi-asserted-by":"publisher","first-page":"104441.83","DOI":"10.1016\/j.nmd.2024.07.092","article-title":"274P Generation of cardiac organoids from DuchenneMuscularDystrophy patient-derived induced pluripotent stem cells: a novel approach to understanding cardiomyopathy","volume":"43","author":"Przymusza\u0142a","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"B69","unstructured":"2024"},{"key":"B70","article-title":"Genetic background and phenotypes in animal models of human diseases","volume-title":"Microbial and phenotypic definition of rats and mice: proceedings of the 1998 US\/Japan conference","year":"1999"},{"key":"B71","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"Rare disease terminology and definitions-A systematic global review: report of the ISPOR rare disease special interest group","volume":"18","author":"Richter","year":"2015","journal-title":"Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2200030","DOI":"10.1002\/adtp.202200030","article-title":"Classical complement pathway inhibition in a \u201chuman-on-A-chip\u201d model of autoimmune demyelinating neuropathies","volume":"5","author":"Rumsey","year":"2022","journal-title":"Adv. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1753","DOI":"10.1002\/mgg3.1753","article-title":"A novel mutation in COL3A1 associates to vascular Ehlers\u2013Danlos syndrome with predominant musculoskeletal involvement","volume":"9","author":"Ruscitti","year":"2021","journal-title":"Mol. Genet. Genomic Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Sch\u00f6ndorf","year":"2014","journal-title":"Nat. Commun."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3389\/fphar.2018.01475","article-title":"Animal models in the pathophysiology of cystic fibrosis","volume":"9","author":"Semaniakou","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.5966\/sctm.2015-0053","article-title":"Skeletal muscle differentiation on a chip shows human donor mesoangioblasts\u2019 efficiency in restoring dystrophin in a Duchenne muscular dystrophy model","volume":"5","author":"Serena","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13023-016-0460-9","article-title":"State of rare disease management in Southeast Asia","volume":"11","author":"Shafie","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1002\/jcsm.13094","article-title":"Engineered skeletal muscle recapitulates human muscle development, regeneration and dystrophy","volume":"13","author":"Shahriyari","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"B79","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1038\/s41467-019-11178-w","article-title":"Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders","volume":"10","author":"Shik Mun","year":"2019","journal-title":"Nat. Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/path.4551","article-title":"A novel human model of the neurodegenerative disease GM1 gangliosidosis using induced pluripotent stem cells demonstrates inflammasome activation","volume":"237","author":"Son","year":"2015","journal-title":"J. Pathol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-024-03316-9","article-title":"Lessons from a negative gene therapy trial for Duchenne muscular dystrophy","author":"Spuler","year":"2024","journal-title":"Nat. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.18203\/2394-6040.ijcmph20241214","article-title":"An update on management of rare diseases in India","volume":"11","author":"Srivastava","year":"2024","journal-title":"Int. J. Community Med. Public Health"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1542\/peds.2008-0635","article-title":"Lysosomal storage disorders in the newborn","volume":"123","author":"Staretz-Chacham","year":"2009","journal-title":"Pediatrics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview","volume":"6","author":"Sun","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1513\/AnnalsATS.202209-829OC","article-title":"Lung function decline in cystic fibrosis: impact of data availability and modeling strategies on clinical interpretations","volume":"20","author":"Szczesniak","year":"2023","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B88","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0002-9440(10)65633-7","article-title":"Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro","volume":"153","author":"Tabary","year":"1998","journal-title":"Am. J. Pathol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2214-109X(24)00056-1","article-title":"The landscape for rare diseases in 2024","volume":"12","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.bbadis.2017.08.011","article-title":"Mechanisms of endothelial cell dysfunction in cystic fibrosis","volume":"1863","author":"Totani","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jcf.2021.03.019","article-title":"Comparative meta-analysis of cystic fibrosis cell models suggests partial endothelial-to-mesenchymal transition","volume":"20","author":"Treps","year":"2021","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"B93","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.E14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell."},{"key":"B94","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-2369-15-72","article-title":"Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?","volume":"15","author":"Waldek","year":"2014","journal-title":"BMC Nephrol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1038\/s41467-023-38766-1","article-title":"South Asian medical cohorts reveal strong founder effects and high rates of homozygosity","volume":"14","author":"Wall","year":"2023","journal-title":"Nat. Commun."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/acn3.50862","article-title":"Environmental and genetic risk factors for MS: an integrated review","volume":"6","author":"Waubant","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10974-019-09535-9","article-title":"What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?","volume":"40","author":"Wells","year":"2019","journal-title":"J. Muscle Res. Cell. Motil."},{"key":"B99","doi-asserted-by":"publisher","first-page":"S186","DOI":"10.1016\/S1353-8020(11)70058-X","article-title":"Mouse models for LRRK2 Parkinson\u2019s disease","volume":"18","author":"Xu","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"B100","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13023-022-02557-6","article-title":"A patient advocating for transparent science in rare disease research","volume":"18","author":"Yang","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/cts.13270","article-title":"The economics of moonshots: value in rare disease drug development","volume":"15","author":"Yates","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3345\/cep.2023.00535","article-title":"Development of orphan drugs for rare diseases","volume":"67","author":"Yoo","year":"2023","journal-title":"Clin. Exp. Pediatr."},{"key":"B103","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/genes14030730","article-title":"Pathophysiological investigation of skeletal deformities of musculocontractural ehlers-danlos syndrome using induced pluripotent stem cells","volume":"14","author":"Yue","year":"2023","journal-title":"Genes."},{"key":"B104","doi-asserted-by":"publisher","first-page":"103461","DOI":"10.1016\/j.scr.2024.103461","article-title":"Establishment of an induced pluripotent stem cell line LEIi019-A from an early-onset retinal dystrophy patient with the autosomal dominant OTX2 c.259G>A variant","volume":"78","author":"Zhang","year":"2024","journal-title":"Stem Cell. Res."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1526306\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T06:43:44Z","timestamp":1737960224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1526306\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":104,"alternative-id":["10.3389\/fcell.2025.1526306"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2025.1526306","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"article-number":"1526306"}}